Pancreatic Cancer Research

ResearcherLithuanian University of Health SciencesActive in the last 2 years

Antanas Gulbinas

ORCID-verified (high confidence, 0.95), identity_conf@1As of 9 November 2026

Matched on ORCID iD 0000-0002-6683-1339; OpenAlex author ID A5065330117. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
14
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: none · 2025: 3 papers · 2026: 1 paper

Papers 12

  1. Overexpression of EMT-related transcription factors SNAI1 and ZEB1 is associated with more aggressive clinicopathological features of pancreatic cancer. Co-author DOI 10.1371/journal.pone.0339964↗
  2. Small-molecule inhibitor BAY synergizes with gemcitabine through AHR inhibition in pancreatic cancer cells. Co-author DOI 10.1016/j.bcp.2025.116798↗
  3. Circulating Cell-Free DNA as a Potential Diagnostic Tool in Pancreatic Cancer: A Comparative Analysis. Co-author DOI 10.1159/000547870↗
  4. Baseline AHR expression shapes immune response to pharmacological modulation in PBMCs from pancreatic cancer patients. Co-author DOI 10.3389/fimmu.2025.1655258↗
  5. Association between AHR Expression and Immune Dysregulation in Pancreatic Ductal Adenocarcinoma: Insights from Comprehensive Immune Profiling of Peripheral Blo… Last author DOI 10.3390/cancers15184639↗
  6. Targeting AHR Increases Pancreatic Cancer Cell Sensitivity to Gemcitabine through the ELAVL1-DCK Pathway. Co-author DOI 10.3390/ijms241713155↗
  7. Dynamic perfusion CT - A promising tool to diagnose pancreatic ductal adenocarcinoma. Co-author DOI 10.1515/med-2021-0228↗
  8. Epigenetic Regulation of APAF-1 Through DNA Methylation in Pancreatic Cancer. Co-author DOI 10.21873/anticanres.14366↗
  9. CT- and MRI-Based Assessment of Body Composition and Pancreatic Fibrosis Reveals High Incidence of Clinically Significant Metabolic Changes That Affect the Qua… Co-author DOI 10.3390/medicina55100649↗
  10. Human antigen R mediated post-transcriptional regulation of inhibitors of apoptosis proteins in pancreatic cancer. Co-author DOI 10.3748/wjg.v25.i2.205↗
  11. Upregulation of cugbp2 increases response of pancreatic cancer cells to chemotherapy. Co-author DOI 10.1007/s00423-015-1364-1↗
  12. Whole blood DNA aberrant methylation in pancreatic adenocarcinoma shows association with the course of the disease: a pilot study. First author DOI 10.1371/journal.pone.0037509↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Žilvinas Dambrauskas · 9 shared papers, 2016–2026 · strength 1.50
  2. Giedrius Barauskas · 6 shared papers, 2012–2026 · strength 0.99
  3. Povilas Ignatavičius · 4 shared papers, 2019–2026 · strength 0.85
  4. Darius Stukas · 4 shared papers, 2023–2025 · strength 0.79
  5. Arenida Bartkevičienė · 4 shared papers, 2023–2025 · strength 0.79
  6. Kęstutis Urbonas · 1 shared paper, 2026 · strength 0.33
  7. Romualdas Riauka · 1 shared paper, 2025 · strength 0.27
  8. Aušra Lukošiūtė - Urbonienė · 2 shared papers, 2019–2020 · strength 0.22
  9. Albertas Daukša · 3 shared papers, 2012–2020 · strength 0.21
  10. Inga Zaborienė · 1 shared paper, 2021 · strength 0.16
  11. Kristina Žvinienė · 1 shared paper, 2021 · strength 0.16
  12. Edita Bieliūnienė · 1 shared paper, 2019 · strength 0.09
  13. Aldona Jakštaitė · 1 shared paper, 2016 · strength 0.06
  14. Osman El-Maarri · 1 shared paper, 2012 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.